Sprycel (dasatinib) is a prescription drug used to treat certain types of leukemia. Sprycel can cause side effects ranging from mild to serious, and some of them can last a long time. Examples include ...

Sprycel (dasatinib) is a prescription drug used to treat certain types of leukemia. Sprycel’s cost may depend on factors such as your dosage, whether you have health insurance, and the pharmacy you ...

Sprycel (dasatinib) is a brand-name drug that’s prescribed for certain types of leukemia in adults and some children. Sprycel comes as a tablet that’s typically taken once per day. The dosage can vary ...

PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. today announced the launch of My SPRYCEL ® (dasatinib) Support, a useful ...

SPRYCEL® (dasatinib) Demonstrates Superior Confirmed Complete Cytogenetic Response Rates Compared to Gleevec®* in Study of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase ...

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE:BMY) and Otsuka America Pharmaceutical, Inc. today announced five-year follow-up results from a Phase 3 randomized, open-label, ...

The expanded approval was supported by data from the Phase 2 multicenter, single-arm CA180-372 study (NCT01460160) which included 78 pediatric patients with newly diagnosed B-cell precursor Ph+ ALL.

NEW YORK (Reuters) - Bristol-Myers Squibb's cancer drug Sprycel was superior to the highly effective Gleevec in treating newly diagnosed patients with chronic myeloid leukemia, researchers reported on ...

Bristol-Myers Squibb Company BMY announced that the FDA has approved a label expansion of the oncology drug, Sprycel. Sprycel tablets are now approved for the treatment of pediatric patients aged one ...

If you and your doctor agree that Sprycel is working well for you, the drug is typically a long-term treatment. As with other drugs, Sprycel can cause side effects. Read on to learn about potential ...

Bristol-Myers Squibb Company BMY announced that the European Commission (EC) has approved its oncology drug Sprycel (dasatinib) in combination with chemotherapy for the treatment of pediatric patients ...